RSS

Ofatumumab

Novartis plans to transition the use of its treatment for certain chronic lymphocytic leukaemia (CLL), Arzerra (ofatumumab), from commercial availability to limited availability via compassionate use programmes in all markets except the US. more

News

Novartis has acquired all remaining rights to GlaxoSmithKline’s (GSK) Ofatumumab more

News